Back to Search Start Over

Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting.

Authors :
Lafferty, Lise
Rance, Jake
Grebely, Jason
Dore, Gregory J
Lloyd, Andrew R
Treloar, Carla
SToP-C Study Group
Source :
International Journal of Drug Policy. Mar2020, Vol. 77, pN.PAG-N.PAG. 1p.
Publication Year :
2020

Abstract

<bold>Background: </bold>Hepatitis C (HCV) infection is highly prevalent within the prison setting. Direct-acting antiviral (DAA) therapies have changed the HCV treatment landscape, offering simple treatment (with minimal side-effects) and high efficacy. These advances have enabled the first real-world study of HCV treatment as prevention (TasP), the Surveillance and Treatment of Prisoners with hepatitis C (SToP-C) study. This paper draws on data from qualitative interviews completed with SToP-C participants following prison-wide DAA treatment scale-up.<bold>Methods: </bold>Semi-structured interviews were undertaken with 23 men in prison following HCV treatment completion to identify ongoing risk practices, perceptions of strategies for HCV prevention within the prison setting, experiences of HCV treatment (as prevention), and perceptions of reinfection following cure. Analysis was undertaken using a counterpublic health lens to identify risks and perceptions of reinfection among people treated for HCV within the prison setting.<bold>Results: </bold>Participants identified a number of challenges of meaningful HCV 'cure' in the absence of increased access to prevention strategies (e.g., opioid agonist therapy and prison needle syringe programs) along with concerns that 'cure' was only temporary whilst incarcerated. 'Cure' status included self-perceptions of being "clean", while also imposing responsibility on the individual to maintain their 'cure' status.<bold>Conclusion: </bold>HCV DAA treatment is provided somewhat under the guise of 'cure is easy', but fails to address the ongoing risk factors experienced by people who inject drugs in prisons, as well as other people in prison who may be at risk of blood-to-blood exposure. Health messaging regarding HCV treatment and treatment for reinfection should be tailored to ensure patient-centred care. Health interventions in prison must address the whole person and the circumstances in which they live, not just the illness. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
09553959
Volume :
77
Database :
Academic Search Index
Journal :
International Journal of Drug Policy
Publication Type :
Academic Journal
Accession number :
142636077
Full Text :
https://doi.org/10.1016/j.drugpo.2020.102693